Gary Anderson works in translational immunopharmacologynusing genetic disease models and clinical cohorts to find molecular mechanisms of lung diseases, especially asthma and COPD. He described the diffusion microkinetic mechanism of long-acting beta-2 agonists and the critical role of IL-4 in murine Th2/T2 lung immunity. In 2008 he proposed the widely adopted “Endotype” concept of disease. His work identified the pathogenic role of SAA, gp130 and the Src family kinases LYN and HCK in lung disease. Earlier, he worked in the Swiss pharma industry and contributed to the discovery and development of the clinical medicines formoterol, indacaterol, omalizumab/anti-IgE and imatininb. His current work on drug development includes otilimab/anti-GM-CSF, elarekibep/PRS-060/AZD1472 anticalin and new inhaled JAG-1 blockers for muco-obstructive disease. He was a co-author of the Lancet Commission on asthma and leads the CURE Asthma initiative.

Professor of Respiratory Medicine in the Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia. Emeritus Director, Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Melbourne. 2008 -2024. Phil is a practising clinician recognised for research of obstructive lung diseases (particularly asthma-COPD). Conducted extensive research of new asthma and COPD therapies. Recently studies have included vocal cord dysfunction/inducible laryngeal obstruction (VCD/ILO), an important and common but neglected condition. Recipient of ongoing Australian NH&MRC funding and has chaired the Australian NH&MRC Grant Review Panel (Respiratory & Sleep Medicine) and served on the NH&MRC Academy. Immediate past-Co-Editor-in-Chief of Respirology, official journal of the TSANZ and APSR. These professional activities reflect a career-long commitment to clinical research, teaching, administration and medical publishing.

Dr Angela Moran is a Respiratory Physician at Christchurch Hospital. She completed a Clinical Research Fellowship with Prof Ian Pavord at the University of Oxford/Oxford NHS Trust Hospitals, where she was an integral member of the Severe Asthma Service. She has extensive experience using biologic therapies to treat severe eosinophilic asthma. Dr Moran has authored a number of publications on asthma and COPD and has presented her research at various international meetings. She enjoys utilising her skills in the Canterbury community as an asthma specialist.